Close Menu

NEW YORK (GenomeWeb) – A team of researchers have developed an array-based classifier that they say can be used to predict whether chemotherapy will be effective on patients with esophageal cancer.

The test relies on a signature that Almac Diagnostics developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.